PMID- 14631913
OWN - NLM
STAT- MEDLINE
DCOM- 20040106
LR  - 20151119
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 142
IP  - 11
DP  - 2003 Nov
TI  - [Matrix metalloproteinases and their tissue inhibitors in malignancies of the 
      female genital tract].
PG  - 786-91, 804
AB  - The matrix metalloproteinases (MMPs) are a family of proteolytic enzymes, which 
      are capable of degradation of the proteins composing the extracellular matrix and 
      basement membrane. Their proteolytic activity depends on their binding to metal 
      Zinc and is controlled by tissue inhibitors of MMP (TIMPs). Degradation of the 
      extracellular matrix and basement membrane is an important component of the 
      process of tumor invasiveness, progression, angiogenesis and metastatic spread. 
      Since MMPs may serve as markers of tumor behavior and as predictors of survival 
      and since synthetic inhibitors of MMP may have a place in the treatment of 
      cancer, researching MMPs and their tissue inhibitors in malignant diseases has 
      attracted growing attention. Studies on MMPs and their tissue inhibitors in 
      malignancies of the female genital tract have shown the following: 1) In ovarian 
      carcinoma and cervical carcinoma, over-expression of MMP-2 and MMP-9 is 
      associated with invasiveness, metastatic spread and poor prognosis; 2) In 
      endometrial carcinoma, MMP-7 (matrilysin) is the main MMP associated with 
      invasiveness, metastatic spread and poor prognosis; 3) In cervical 
      intra-epithelial neoplasia (CIN), measuring MMP-2 can assist in identifying 
      high-risk for progression CIN I and CIN II; 4). In vulvar squamous cell 
      carcinoma, over-expression of MMP-13 is associated with invasiveness, metastatic 
      spread and poor prognosis. It is speculated that using synthetic drugs that 
      inhibit MMPs in combination with conventional chemotherapy may contribute to the 
      improvement of treatment results in cancer patients.
FAU - Piura, B
AU  - Piura B
AD  - Unit of Gynecologic Oncology, Department of Obstetrics and Gynecology, Soroka 
      Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, 
      Beer Sheva, Israel.
FAU - Rabinovich, A
AU  - Rabinovich A
FAU - Huleihel, M
AU  - Huleihel M
LA  - heb
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Tissue Inhibitor of Metalloproteinases)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
SB  - IM
MH  - Biomarkers, Tumor/analysis
MH  - Female
MH  - Genital Neoplasms, Female/*enzymology/*pathology
MH  - Humans
MH  - Matrix Metalloproteinases/genetics/*metabolism
MH  - Tissue Inhibitor of Metalloproteinases/genetics/*metabolism
RF  - 32
EDAT- 2003/11/25 05:00
MHDA- 2004/01/07 05:00
CRDT- 2003/11/25 05:00
PHST- 2003/11/25 05:00 [pubmed]
PHST- 2004/01/07 05:00 [medline]
PHST- 2003/11/25 05:00 [entrez]
PST - ppublish
SO  - Harefuah. 2003 Nov;142(11):786-91, 804.